Vol. 5 No. 6 (2025)
Reimbursement Reviews

Faricimab (Vabysmo)

decorative image of the issue cover

Published June 18, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses faricimab injection (Vabysmo) 6 mg/0.05 mL solution for intravitreal injection.
  • Indication: For the treatment of macular edema secondary to retinal vein occlusion.